ArticleInfection and drug resistance2018
The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Association of procalcitonin with voriconazole concentrations: a retrospective cohort study.BMC infectious diseases · 2024Article
- A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel.Scientific reports · 2024Article
- Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity.Clinical pharmacology and therapeutics · 2023Article
- Establishment of a mathematical prediction model for voriconazole stable maintenance dose: a prospective study.Frontiers in cellular and infection microbiology · 2023Observational
- HKG: an open genetic variant database of 205 Hong Kong cantonese exomes.NAR genomics and bioinformatics · 2022Article
- Inflammation Affects Liver Function and the Metabolism of Voriconazole to Voriconazole-N-Oxide in Adult and Elderly Patients.Frontiers in pharmacology · 2022Article
- A Pharmacogenetic Study ofJournal of personalized medicine · 2021Article
- PharmVar GeneFocus: CYP2C19.Clinical pharmacology and therapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCYP/CYP450 2C19 (CYP2C19) is a highly polymorphic enzyme and exhibits individual differences in metabolic activity. The purpose of this research was mainly to explore the catalytic activities of 30 CYP2C19 variants on the substrate voriconazole in vitro, including 24 novel CYP2C19 variants (2C19.2E-.2H, .2J, .3C, .29-.33, L16F, 35FS, R124Q, R125G, T130M, N231T, M255T, R261W, N277K, S303N, I327T, N403I, and A430V) found in Chinese Han population for the first time.
methodsThese CYP2C19 variants were expressed in
resultsFrom the results, when compared to CYP2C19.1, most variants exhibited either reduced
conclusionThis is the first study to report the effects of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.